AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Syndromic Multiplex Diagnostic Markets, 2019 & 2020-2024: Strategies and Trends, Forecasts by Respiratory, Sepsis, GI - ResearchAndMarkets.com

November 4, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 4, 2019--

The “Syndromic Multiplex Diagnostic Markets - Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) & by Country - With Market Analysis, Executive Guides & Customization 2020 to 2024” report has been added to ResearchAndMarkets.com’s offering.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician’s Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.

The report forecasts the market size out to 2024. In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.

Key Topics Covered:

1. Introduction and Market Definition

1.1 What are Syndromic Multiplex Tests?

1.2 Syndromic Testing - the quiet revolution in diagnostics

1.2.1 Syndromic Testing - more than Panels

1.3 Market Definition

1.3.1 Multiplex Market Size

1.3.2 Panel Market Size

1.3.2 Currency

1.3.3 Years

1.4 Methodology

1.4.1 Authors

1.4.2 Sources

1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective

1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Guide to the Pathogens

2.1 HIV - Human Immunodeficiency Virus (AIDS)

2.1.1 Virology

2.1.1.1 Classification

2.1.1.2 Structure and genome

2.1.1.3 Tropism

2.1.1.4 Replication cycle

2.1.1.5 Genetic variability

2.1.2 Diagnosis

2.1.3 Testing

2.1.3.1 Antibody tests

2.1.3.2 Point of Care Tests (POCT)

2.1.3.4 Antigen Tests

2.1.3.5 Nucleic acid-based tests (NAT)

2.1.3.6 Other tests used in HIV treatment

2.2 HBV - Hepatitis B

2.2.1 Virology

2.2.1.1 Genome

2.2.1.2 Pathogenesis

2.2.1.3 Hepatitis B virus replication

2.2.1.4 Serotypes and genotypes

2.2.2 Mechanisms

2.2.3 Diagnosis

2.2.4 Market Opportunity Analysis

2.3 HCV - Hepatitis C

2.3.1 Taxonomy

2.3.2.1 Structure

2.3.2.2 Genome

2.3.3 Molecular biology

2.3.4 Replication

2.3.5 Genotypes

2.3.1.1 Clinical importance

2.3.6 Market Opportunity Analysis

2.4 HPV - Human papillomavirus

2.4.1 Virology

2.4.1.1 E6/E7 proteins

2.4.1.2 Role in cancer

2.4.1.3 E2 research

2.4.1.4 Latency period

2.4.1.5 Clearance

2.4.2 Diagnosis

2.4.2.1 Cervical testing

2.4.2.2 Oral testing

2.4.2.3 Testing men

2.4.2.4 Other testing

2.4.3 Market Opportunity Analysis

2.5 Influenza

2.5.1 Virology

2.5.1.1 Types of virus

2.5.1.2 Influenzavirus A

2.5.1.3 Influenzavirus B

2.5.1.4 Influenzavirus C

2.5.1.5 Structure, properties, and subtype nomenclature

2.5.1.6 Replication

2.5.2 Testing

2.5.2.1 Advantages/Disadvantages of Molecular Assays

2.5.3 Market Opportunity Analysis

2.6 CTGC - Chlamydia/Gonorhea

2.6.1 Gonorrhea

2.6.1.1 Diagnosis

2.6.1.2 Screening

2.6.2 Chlamydia

2.6.2.1 Diagnosis

2.6.2.2 Screening

2.6.3 Testing

2.6.3.1 Nucleic acid amplification tests (NAATs).

2.6.3.2 Performance of NAAT Tests

2.6.4 Market Opportunity Analysis

2.7 Tuberculosis

2.7.1 Mycobacteria

2.7.2 Diagnosis

2.7.2.1 Active tuberculosis

2.7.2.2 Latent tuberculosis

2.7.3 Epidemiology

2.7.4 Molecular Diagnostic Tests

2.7.5 Market Opportunity Analysis

2.8 MRSA - Methicillin-resistant Staphylococcus aureus

2.8.1 Diagnosis

2.8.2 FDA Approved Molecular Tests

2.8.3 Market Opportunity Analysis

2.9 VRE - Vancomycin-resistant Enterococcus

2.9.1 FDA Approved MDx Tests for VRE

2.9.2 Market Opportunity Analysis

3. Industry Overview

3.1 Industry Participants

3.1.1 IVD Supplier

3.1.2 Independent lab specialized/esoteric

3.1.3 Independent lab national/regional

3.1.4 Independent lab analytical

3.1.5 Public National/regional lab

3.1.6 Hospital lab

3.1.7 Physician lab

3.1.8 Audit body

3.2 The Clinical Laboratory Market Segments

3.2.1 Traditional Market Segmentation

3.2.2 Laboratory Focus and Segmentation

3.2.3 Segmenting the Syndromic Testing Market

3.3 Industry Structure

3.3.1 Hospital Testing Share

3.3.2 Economies of Scale

3.3.2.1 Hospital vs. Central Lab

3.3.3 Physician Office Lab’s

3.3.4 Physician’s and POCT

4. Market Trends

4.1 Factors Driving Growth

4.1.1 Speed of Diagnosis

4.1.2 Effect of Syndromic Testing on Costs

4.1.3 Point of Care Advantage

4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk

4.1.5 Single Visits

4.1.6 Improvement in Outcomes.

4.2 Factors Limiting Growth

4.2.1 Lower Prices

4.2.2 Administration/reimbursement

4.2.3 Infectious Disease is Declining But

4.2.4 Wellness Hurts

4.2.5 Economic Growth improves Living Standards

4.3 Instrumentation and Automation

4.3.1 Instruments Key to Market Share

4.3.2 The Shrinking Machine.

4.3.3 Syndrome Testing Moving to Big Instruments?

4.4 Diagnostic Technology Development

4.4.1 Comparing Syndrome and Targeted Testing

4.4.2 The Multiplex Paradigm Shift

4.4.2 The Sepsis Testing Market - Bellwether for Syndromics

4.4.3 The Single Visit and AntiMicrobial Resistance

4.4.4 Syndromics drives POCT adoption

4.4.5 A Big Future for PCR?

5. Syndromic Testing Recent Developments

6. Profiles of Key Syndromic Testing Companies

7. Global Market Size

7.1 Syndromic Global Market Size by Country with Charts

7.2 Syndromic Global Market Size by Syndrome with Charts

8. Global Market by Syndrome

8.1 Respiratory Syndrome Market

8.2 GI-Enteric Syndrome Market

8.3 Blood-Sepsis Syndrome Market

8.4 Meningitis Syndrome Market

8.5 Sexually Transmitted Disease Syndrome Market

8.6 Other Syndrome Market

9. Panel Testing Market - Volumes and Price Forecast with MDx Share

9.1 Respiratory Panel Market

9.2 GI-Enteric Panel Market

9.3 Blood-Sepsis Panel Market

9.4 Meningitis Panel Market

9.5 Sexually Transmitted Disease Panel Market

9.6 Other Panel Market

Appendices

I. United States Medicare System: 2019 Clinical Laboratory Fees Schedule

II. FDA Approved Microbial Tests

For more information about this report visit https://www.researchandmarkets.com/r/ibme5s

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005421/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/04/2019 07:09 AM/DISC: 11/04/2019 07:09 AM

http://www.businesswire.com/news/home/20191104005421/en